ReviewIndian heart journal2024
Apolipoprotein B - An ideal biomarker for atherosclerosis?
Review in Indian heart journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials.Cardiovascular diabetology · 2025Trial
- Aptamer-based colorimetric assay on poly(allylamine)-blended polycaprolactone electrospun nanofibers for CD36 detection.Mikrochimica acta · 2026Article
- Beneficial Changes in Apolipoprotein Concentrations After Bariatric Surgery in Obese Women.Metabolites · 2026Article
- Predictive value of non-fasting apolipoprotein B/apolipoprotein A-1 ratio combined with systatin C for severe coronary artery stenosis in patients who undergo coronary angiography.Journal of cardiothoracic surgery · 2026Article
- Correlation of Lp(a), ApoB and oxLDL with Endothelial Damage Reading in Patients with Different Degrees of Coronary Atherosclerosis.International journal of molecular sciences · 2026Article
- Whole-exome sequencing in obstructive coronary artery disease identifies rare and novel variants in cardiac arrhythmia and pulmonary arterial hypertension-associated genes.Biomolecules & biomedicine · 2026Article
- RNA-Targeted Therapeutics for Lipid Metabolic Disorders: From Bench to Bedside.Research (Washington, D.C.) · 2026Article
- Inflammation and dyslipidaemia in combined diabetes and tuberculosis; a cohort study.iScience · 2025Article
- Cardiovascular disease risk factors are associated with conventional lipids and apolipoproteins in South African adults of African ancestry.Lipids in health and disease · 2025Article
- Apolipoprotein B and Glycemic Dysregulation: New Predictors of Type 2 Diabetes in High-Cardiovascular-Risk Populations.Journal of personalized medicine · 2025Article
- Lipids dysregulation in diseases: core concepts, targets and treatment strategies.Lipids in health and disease · 2025Review
- Laboratory-derived inflammatory ratios as a novel diagnostic model for premature coronary artery disease.Frontiers in endocrinology · 2025Article
- Serum Apolipoprotein B Levels and Apolipoprotein B/Apolipoprotein A1 Ratio as Predictors of Dyslipidemia Risk in Patients Treated with Second-Generation Antipsychotics: A Retrospective Cohort Study.Neuropsychiatric disease and treatment · 2025Article
- The Potential Causal Association of Apolipoprotein A and B and Age-Related Macular Degeneration: A Mendelian Randomisation Study.Biomedicines · 2024Article
- Association between Apo B, LDL-R and PCSK9 gene polymorphisms with coronary artery diseases in Egyptians.Molecular biology reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review article describes the pathophysiological mechanisms linking Apolipoprotein B (Apo-B) and atherosclerosis, summarizes the existing evidence on Apo B as a predictor of atherosclerotic cardiovascular disease and recommendations of (inter)national treatment guidelines regarding Apo B in dyslipidemia management. A single Apo B molecule is present in every particle of very low-density lipoprotein, intermediate density lipoprotein, low density lipoprotein, and lipoprotein(a). This unique single Apo B per particle ratio makes plasma Apo B concentration a direct measure of the number of circulating atherogenic lipoproteins. This review of global evidence on Apo B as a biomarker for atherosclerosis confirms that Apo B is a single atherogenic lipid marker present in all lipids sub-fractions except HDL-C, and thus, Apo B integrates and extends the information from triglycerides and cholesterol, which could simplify and improve care for atherosclerotic cardiovascular disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.